LOUISVILLE, Ky.--(BUSINESS WIRE)--Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has received its final investment of $250,000 from the Commonwealth Seed Capital (CSC), an entity established by the Kentucky Economic Development Partnership Board to invest funds in support of seed-stage technology companies in Kentucky. This final investment was received ahead of schedule based on the progress and milestones ACT has achieved since starting operations in October 2007 and brings CSC’s total amount invested in ACT to $500,000.
